Targacept Inc. (CBIO) Rating Reiterated by HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Targacept Inc. (NASDAQ:CBIO) in a research report report published on Thursday. HC Wainwright currently has a $3.50 price target on the biopharmaceutical company’s stock.
Separately, Rodman & Renshaw initiated coverage on Targacept in a research report on Thursday, June 30th. They issued a buy rating and a $3.50 target price on the stock.
Targacept (NASDAQ:CBIO) opened at 1.11 on Thursday. The stock’s market cap is $13.14 million. Targacept has a 52 week low of $1.05 and a 52 week high of $6.04. The company has a 50-day moving average price of $1.24 and a 200-day moving average price of $1.42.
Targacept (NASDAQ:CBIO) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.11. Targacept had a negative net margin of 4,155.13% and a negative return on equity of 62.53%. Equities research analysts anticipate that Targacept will post ($1.40) EPS for the current year.
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Targacept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Targacept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.